MyoKardia Shares Skyrocket On Promising Phase II Data In HCM
Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet medical need.
Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet medical need.